SI20305A - Kristali natrijeve soli pravastatina - Google Patents

Kristali natrijeve soli pravastatina Download PDF

Info

Publication number
SI20305A
SI20305A SI9900191A SI9900191A SI20305A SI 20305 A SI20305 A SI 20305A SI 9900191 A SI9900191 A SI 9900191A SI 9900191 A SI9900191 A SI 9900191A SI 20305 A SI20305 A SI 20305A
Authority
SI
Slovenia
Prior art keywords
sodium salt
pravastatin sodium
pravastatin
ethyl acetate
crystals
Prior art date
Application number
SI9900191A
Other languages
English (en)
Slovenian (sl)
Inventor
Zlatko Pflaum
Original Assignee
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI20305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority to SI9900191A priority Critical patent/SI20305A/sl
Priority to JP2001515281A priority patent/JP2003506424A/ja
Priority to KR1020077015051A priority patent/KR20070086847A/ko
Priority to AU60109/00A priority patent/AU782143B2/en
Priority to IL14805000A priority patent/IL148050A0/xx
Priority to CNB008113653A priority patent/CN1205172C/zh
Priority to US10/049,093 priority patent/US7078558B1/en
Priority to NZ516685A priority patent/NZ516685A/en
Priority to YU5402A priority patent/YU5402A/sh
Priority to EP00946239A priority patent/EP1200385B2/en
Priority to SI200030653T priority patent/SI1200385T2/sl
Priority to SK174-2002A priority patent/SK1742002A3/sk
Priority to CZ2002414A priority patent/CZ2002414A3/cs
Priority to KR1020027001231A priority patent/KR100766928B1/ko
Priority to ES00946239T priority patent/ES2235911T5/es
Priority to DE60017568T priority patent/DE60017568T2/de
Priority to PCT/IB2000/001103 priority patent/WO2001010813A1/en
Priority to HU0202536A priority patent/HUP0202536A3/hu
Priority to DK00946239T priority patent/DK1200385T3/da
Priority to CA002379335A priority patent/CA2379335A1/en
Priority to RU2002102862/04A priority patent/RU2247711C2/ru
Priority to PL00365850A priority patent/PL365850A1/xx
Priority to PT00946239T priority patent/PT1200385E/pt
Priority to AT00946239T priority patent/ATE287389T1/de
Publication of SI20305A publication Critical patent/SI20305A/sl
Priority to ZA200200437A priority patent/ZA200200437B/en
Priority to HR20020106A priority patent/HRP20020106A2/hr
Priority to BG106389A priority patent/BG65368B1/bg
Priority to IL148050A priority patent/IL148050A/en
Priority to US10/408,012 priority patent/US6740775B1/en
Priority to US11/400,872 priority patent/US20060183929A1/en
Priority to IL187261A priority patent/IL187261A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI9900191A 1998-09-18 1999-08-06 Kristali natrijeve soli pravastatina SI20305A (sl)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SI9900191A SI20305A (sl) 1999-08-06 1999-08-06 Kristali natrijeve soli pravastatina
KR1020077015051A KR20070086847A (ko) 1999-08-06 2000-08-04 결정형의 프라바스타틴 소듐염
ES00946239T ES2235911T5 (es) 1999-08-06 2000-08-04 Procedimiento para la preparación de cristales de la sal sódica de pravastatina.
HU0202536A HUP0202536A3 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
DE60017568T DE60017568T2 (de) 1999-08-06 2000-08-04 Kristalle des natriumsalzes von pravastatin
IL14805000A IL148050A0 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
CNB008113653A CN1205172C (zh) 1999-08-06 2000-08-04 普伐他汀钠盐晶体
US10/049,093 US7078558B1 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
NZ516685A NZ516685A (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
YU5402A YU5402A (sh) 1999-08-06 2000-08-04 Kristali natrijumove soli pravastatina
EP00946239A EP1200385B2 (en) 1999-08-06 2000-08-04 Process for the preparation of crystals of the sodium salt of pravastatin
SI200030653T SI1200385T2 (sl) 1999-08-06 2000-08-04 Kristali natrijeve soli pravastatina
SK174-2002A SK1742002A3 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
CZ2002414A CZ2002414A3 (cs) 1999-08-06 2000-08-04 Krystaly sodné soli pravastatinu
KR1020027001231A KR100766928B1 (ko) 1999-08-06 2000-08-04 결정형의 프라바스타틴 소듐염
JP2001515281A JP2003506424A (ja) 1999-08-06 2000-08-04 プラバスタチンナトリウムの結晶
AU60109/00A AU782143B2 (en) 1998-09-18 2000-08-04 Crystals of the sodium salt of pravastatin
AT00946239T ATE287389T1 (de) 1999-08-06 2000-08-04 Kristalle des natriumsalzes von pravastatin
PCT/IB2000/001103 WO2001010813A1 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
DK00946239T DK1200385T3 (da) 1999-08-06 2000-08-04 Krystaller af natriumsalt af pravastatin
CA002379335A CA2379335A1 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
RU2002102862/04A RU2247711C2 (ru) 1999-08-06 2000-08-04 Кристаллическая форма натриевой соли правастатина
PL00365850A PL365850A1 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin
PT00946239T PT1200385E (pt) 1999-08-06 2000-08-04 Cristais do sal de sodio de pravastatina
ZA200200437A ZA200200437B (en) 1999-08-06 2002-01-17 Crystals of the sodium salt of pravastatin.
HR20020106A HRP20020106A2 (en) 1999-08-06 2002-02-04 Crystals of the sodium salt of pravastatin
BG106389A BG65368B1 (bg) 1999-08-06 2002-02-05 Кристали на натриевата сол на правастатин
IL148050A IL148050A (en) 1999-08-06 2002-02-06 Crystals of pravastatin sodium salt
US10/408,012 US6740775B1 (en) 1999-08-06 2003-04-04 Crystalline sodium salt of pravastatin
US11/400,872 US20060183929A1 (en) 1999-08-06 2006-04-10 Crystals of the sodium salt of pravastatin
IL187261A IL187261A0 (en) 1999-08-06 2007-11-08 Crystals of the sodium salt of pravastatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9900191A SI20305A (sl) 1999-08-06 1999-08-06 Kristali natrijeve soli pravastatina

Publications (1)

Publication Number Publication Date
SI20305A true SI20305A (sl) 2001-02-28

Family

ID=20432515

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9900191A SI20305A (sl) 1998-09-18 1999-08-06 Kristali natrijeve soli pravastatina
SI200030653T SI1200385T2 (sl) 1999-08-06 2000-08-04 Kristali natrijeve soli pravastatina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200030653T SI1200385T2 (sl) 1999-08-06 2000-08-04 Kristali natrijeve soli pravastatina

Country Status (24)

Country Link
US (3) US7078558B1 (ko)
EP (1) EP1200385B2 (ko)
JP (1) JP2003506424A (ko)
KR (2) KR20070086847A (ko)
CN (1) CN1205172C (ko)
AT (1) ATE287389T1 (ko)
BG (1) BG65368B1 (ko)
CA (1) CA2379335A1 (ko)
CZ (1) CZ2002414A3 (ko)
DE (1) DE60017568T2 (ko)
DK (1) DK1200385T3 (ko)
ES (1) ES2235911T5 (ko)
HR (1) HRP20020106A2 (ko)
HU (1) HUP0202536A3 (ko)
IL (3) IL148050A0 (ko)
NZ (1) NZ516685A (ko)
PL (1) PL365850A1 (ko)
PT (1) PT1200385E (ko)
RU (1) RU2247711C2 (ko)
SI (2) SI20305A (ko)
SK (1) SK1742002A3 (ko)
WO (1) WO2001010813A1 (ko)
YU (1) YU5402A (ko)
ZA (1) ZA200200437B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
KR20020062340A (ko) * 1999-12-14 2002-07-25 비오갈 기오기스제르갸르 알티. 신규 형태의 프라바스타틴 나트륨
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
ATE452871T1 (de) 2002-03-18 2010-01-15 Biocon Ltd Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse
WO2004110585A1 (ja) * 2003-06-10 2004-12-23 Taisho Pharmaceutical Co., Ltd. 放射球状晶析物およびその製造方法並びにこれを利用するドライパウダー製剤
CN1293874C (zh) * 2003-08-18 2007-01-10 李朝晖 以洛伐他汀盐为主要活性成分的中药红曲及其制剂
JP2007512366A (ja) 2003-11-24 2007-05-17 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ プラバスタチンの精製方法
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
WO2006017698A2 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1833780A1 (en) * 2005-02-09 2007-09-19 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Methods of making pravastatin sodium
JP4895510B2 (ja) * 2005-02-23 2012-03-14 株式会社トクヤマ バリオールアミンの製造方法
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
WO2009148709A1 (en) * 2008-04-16 2009-12-10 University Of Utah Research Foundation Pharmacological targeting of vascular malformations
CN101348476B (zh) * 2008-09-05 2011-05-11 丽珠集团新北江制药股份有限公司 一种制备4,5,6,7-四氢普伐他汀及其钠盐的方法和固体结晶形式
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
CN102533893A (zh) * 2010-12-09 2012-07-04 浙江海正药业股份有限公司 一种制备莫那可林j的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
US6098031A (en) 1998-03-05 2000-08-01 Gsi Lumonics, Inc. Versatile method and system for high speed, 3D imaging of microscopic targets
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
CA2361701C (en) † 1999-02-03 2007-04-10 Institute For Drug Research Ltd. Microbial process for preparing pravastatin

Also Published As

Publication number Publication date
US6740775B1 (en) 2004-05-25
DE60017568T2 (de) 2006-03-30
HUP0202536A2 (hu) 2003-01-28
HRP20020106A2 (en) 2003-04-30
NZ516685A (en) 2004-01-30
DK1200385T3 (da) 2005-05-23
IL148050A0 (en) 2002-09-12
WO2001010813A1 (en) 2001-02-15
PL365850A1 (en) 2005-01-10
ES2235911T3 (es) 2005-07-16
RU2247711C2 (ru) 2005-03-10
IL148050A (en) 2008-11-03
EP1200385A1 (en) 2002-05-02
US20060183929A1 (en) 2006-08-17
YU5402A (sh) 2005-03-15
BG65368B1 (bg) 2008-04-30
KR20020025204A (ko) 2002-04-03
JP2003506424A (ja) 2003-02-18
EP1200385B1 (en) 2005-01-19
CN1368948A (zh) 2002-09-11
SI1200385T1 (en) 2005-08-31
KR100766928B1 (ko) 2007-10-17
PT1200385E (pt) 2005-04-29
CA2379335A1 (en) 2001-02-15
EP1200385B2 (en) 2011-09-21
ATE287389T1 (de) 2005-02-15
CZ2002414A3 (cs) 2002-07-17
HUP0202536A3 (en) 2003-04-28
ZA200200437B (en) 2003-03-26
BG106389A (en) 2002-09-30
IL187261A0 (en) 2008-02-09
KR20070086847A (ko) 2007-08-27
ES2235911T5 (es) 2012-02-27
SK1742002A3 (en) 2002-06-04
US7078558B1 (en) 2006-07-18
SI1200385T2 (sl) 2012-02-29
DE60017568D1 (de) 2005-02-24
CN1205172C (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
SI20305A (sl) Kristali natrijeve soli pravastatina
KR101440982B1 (ko) 라퀴니모드 나트륨의 결정 및 이의 제조방법
CA2551050C (en) Crystal form of quinoline compound and process for its production
IL226616A (en) Polymorph of chemically pure nor – udca, methods for its preparation and uses for the treatment of liver disease
US11673918B2 (en) Method of manufacturing a pharmaceutical composition
AU2008209271B2 (en) A novel crystalline mycophenolate sodium polymorph and processes to manufacture same
AU782143B2 (en) Crystals of the sodium salt of pravastatin
US20040242670A1 (en) Process for preparation of amorphous atorvastatin calcium
KR101101319B1 (ko) 불순한 비결정성 프라바스타틴 나트륨염을 정제하여 결정성프라바스타틴 나트륨염을 제조하는 방법
CN111217781B (zh) 贝前列素-314d晶体和其制备方法
KR20090056527A (ko) 아토르바스타틴 칼슘염의 개선된 제조방법
NZ237002A (en) Method for resolving cis 3-amino-4-(2-(2-furyl)eth-1-yl)-1-methoxycarbonylmethyl-azetidin-2-one into its enantiomers and the resolved keto-l-gulonic acid hydrate salt thereof
WO2013155592A1 (en) Crystal forms of golotimod and process for its manufacturing
JPH0971575A (ja) 新規な結晶型スルホンアミド化合物
MXPA06007435A (en) Crystal form of quinoline compound and process for its production

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20090827